TLPPF (Telix Pharmaceuticals) Total Inventories : $20.5 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Total Inventories?

Telix Pharmaceuticals's total inventories for the quarter that ended in Jun. 2024 was $20.5 Mil. Telix Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Jun. 2024 was $16.0 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Telix Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was $-0.28.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Telix Pharmaceuticals's Days Inventory for the six months ended in Jun. 2024 was 35.24.

Inventory Turnover measures how fast the company turns over its inventory within a year. Telix Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2024 was 5.18.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Telix Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.07.

Telix Pharmaceuticals Total Inventories Historical Data

The historical data trend for Telix Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Total Inventories Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

0.37

0.48

2.47

5.72

11.59

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Inventories	Get a 7-Day Free Trial									4.59	5.72	8.46	11.59	20.45

Telix Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Telix Pharmaceuticals (OTCPK:TLPPF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Telix Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is

	Net-Net Working Capital Per Share (Q: Jun. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(78.909	+	0.75 * 59.394	+	0.5 * 20.454	-	227.081
-	0	-	0)	/	334.232
=	-0.28

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Telix Pharmaceuticals's Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2024 )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
	=	16.02	/	82.961	*	365 / 2
	=	35.24

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Telix Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2024 )	/	Average Total Inventories (Q: Jun. 2024 )
	=	82.961	/	16.02
	=	5.18

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Telix Pharmaceuticals's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	16.02	/	238.201
	=	0.07

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Telix Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

TLX:USA T3X:Germany TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.